Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

GlobeNewswire November 30, 2020

Sunesis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire November 16, 2020

Sunesis Pharmaceuticals to Host Conference Call on November 16th to Discuss Third Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire November 9, 2020

Sunesis Pharmaceuticals Announces Presentation of SNS-510 Preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 12, 2020

Sunesis Pharmaceuticals Announces Participation at Upcoming Investor Conferences

GlobeNewswire September 3, 2020

Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split

GlobeNewswire September 2, 2020

Sunesis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire August 11, 2020

Sunesis Pharmaceuticals to Host Conference Call on August 11th to Discuss Second Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire August 4, 2020

Sunesis Announces Pricing of $12 Million Offering of Common Stock

GlobeNewswire July 29, 2020

Sunesis Announces Proposed Public Offering of Common Stock

GlobeNewswire July 28, 2020

Sunesis Pharmaceuticals Provides Corporate Update

GlobeNewswire July 7, 2020

Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program

GlobeNewswire June 23, 2020

Sunesis Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire May 7, 2020

Sunesis Pharmaceuticals to Host Conference Call on May 7th to Discuss First Quarter 2020 Financial Results and Recent Highlights

GlobeNewswire April 30, 2020

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights

GlobeNewswire March 10, 2020

Sunesis Pharmaceuticals to Host Conference Call on March 10th to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Highlights

GlobeNewswire March 3, 2020

Sunesis Pharmaceuticals to Present at the 40th Annual Cowen Health Care Conference

GlobeNewswire February 25, 2020

Sunesis Pharmaceuticals Announces Data from Ongoing Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies

GlobeNewswire December 5, 2019

Sunesis Pharmaceuticals Reports Third Quarter 2019 Financial Results and Recent Highlights

GlobeNewswire November 12, 2019

Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference

GlobeNewswire November 8, 2019